Mechanism of Action and Receptor Profile
The pharmacodynamics of norepinephrine is based on its direct stimulatory effect on adrenergic receptors. The drug exhibits high affinity for two main receptor groups:
- Alpha-adrenergic receptors: Powerful stimulation of α1- and α2-adrenergic receptors located in blood vessels occurs, leading to generalized vasospasm.
- Beta-adrenergic receptors: The drug actively targets myocardial β1-adrenergic receptors.
A key pharmacological feature distinguishing it from epinephrine (adrenaline) is that norepinephrine has virtually no effect on β2-adrenergic receptors. Because there is no stimulation of vascular β2 receptors (which mediate vasodilation), norepinephrine administration is not followed by a secondary phase of blood pressure decline.
Cardiovascular Effects
Hemodynamic effects develop rapidly but are short-lived. The primary clinical effect is a marked increase in blood pressure (BP) driven by vasoconstriction.
Despite the direct stimulatory effect on cardiac β1 receptors (which increases contractility and stroke volume), cardiac output ultimately does not increase. This is due to a complex compensatory mechanism—reflex bradycardia:
- A sharp rise in blood pressure causes mechanical stretching and activation of baroreceptors located in the aortic arch.
- Afferent impulses reach the medulla oblongata, stimulating the vagus nerve (n. vagus) nucleus.
- Parasympathetic inhibitory tone on the sinoatrial node increases.
- Heart rate (HR) decreases accordingly, compensating for the increased stroke volume.
Pharmacological test: This reflex response can be blocked. Pretreatment with atropine (a muscarinic receptor antagonist) eliminates vagal influence, preventing bradycardia.
Pharmacokinetics and Administration Guidelines
The drug molecule is extremely unstable in the body, which dictates strict rules for its administration. Oral intake is entirely ineffective because the active substance is rapidly degraded in the gastrointestinal tract.
Intramuscular and subcutaneous injections are strictly contraindicated. Powerful alpha-receptor stimulation causes severe local vasospasm at the injection site, leading to profound ischemia and subsequent tissue necrosis.
The only appropriate route of administration is intravenous. A single bolus injection lasts only a few minutes. This rapid inactivation is explained by two factors: active reuptake by adrenergic nerve terminals and enzymatic degradation (by monoamine oxidase [MAO] and catechol-O-methyltransferase [COMT]). To maintain a stable therapeutic effect, the drug is administered via continuous intravenous infusion. Metabolites and a small fraction of unchanged drug are excreted by the kidneys.
Clinical Profile: Indications and Risks
The sole absolute indication for norepinephrine is conditions accompanied by acute, life-threatening hypotension (acute shock states).
Adverse effects include:
- Headache (due to abrupt changes in cerebral vascular tone and rising blood pressure);
- Cardiac arrhythmias;
- Respiratory disturbances.
Contraindications are extensive. The drug must not be used in severe atherosclerosis, cardiac decompensation, or atrioventricular block. Drug interactions require special attention: norepinephrine is contraindicated during halogenated general anesthesia (such as halothane). Halothane sensitizes the myocardium to catecholamines, and administering norepinephrine in this setting carries an extremely high risk of fatal arrhythmias.